The Organ Protection of Astragalus in Subjects With Metabolic Syndrome

LanZhou University210 enrolled

Overview

Metabolic syndrome have the damages on tissues and organs in heart、kindey and vessels. In this study, prospective randomized, controlled, parallel designed ,different doses of Astragalus Mongolia, Gansu Longxi produce treat on the MS patients, and then use real-time quantitative PCR and Western Blotting to detect the index of oxidative stress 、angiotensin-converting enzyme 2 mRNA expression and proteins.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

210

Conditions

Metabolic Syndrome

Interventions

low dose AstragalusDRUG

high dose astagalusDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. age 18 years or older, meet the diagnostic criteria of MS 2. non-allergic with the astragalus 3. agree to conduct clinical trials and those who signed the informed consent Exclusion Criteria: 1. patients with resistant hypertension 2. renal disease requiring dialysis 3. heart failure NYHA ⅢorⅣ; 4. complications of diabetes 5. arteritis 6. cancer 7. thyroid disease 8. unstable coronary heart disease 9. peripheral vascular disease 10. acute cerebral vascular disease11.pregnancy、 planned pregnancy 11. patients with anti-oxidants 12. acute infection 13. other organic dysfunction, such as the liver, respiratory system, blood system, and other rheumatic diseases.

Locations (1)

Lanzhou University Second Hospital

Lanzhou, Gansu, China

Outcomes

Primary Outcomes

index of cardiac function

ues echocardiography to measure the cardiac function

Time frame: one year

Secondary Outcomes

blood pressure

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.